December 2025 in “Scientific Reports” Valproic acid helps hair follicle stem cells survive better in low oxygen and glucose conditions.
65 citations
,
April 2000 in “The Laryngoscope” Clotrimazole, miconazole, and tolnaftate are likely safe, but gentian violet is risky.
May 2022 in “Dermatologic therapy” Combining PRP with follicular transplantation improves vitiligo treatment better than follicular transplantation alone.
December 2020 in “American Journal of Transplantation” Early recognition and treatment of VATS in transplant patients improve outcomes.
December 2024 in “International Journal of Molecular Sciences” Platelet-rich fibrin may help reduce nonmelanoma skin cancer cell growth.
March 2024 in “Cancer Research” Eliminating senescent cells can prevent and reverse chemotherapy-induced peripheral neuropathy.
21 citations
,
March 2022 in “Pharmaceuticals” The new Brigatinib nanocarrier is more effective against lung cancer cells than the free drug.
September 2024 in “Indian Journal of Dermatology Venereology and Leprology” Mesotherapy with bicalutamide has limited effectiveness for female hair loss.
March 2026 in “SHILAP Revista de lepidopterología” Rituximab may cause skin issues, but baricitinib can help improve them.
April 2016 in “The journal of investigative dermatology/Journal of investigative dermatology” Combining UVB irradiation and anti-CD154 antibody improves hair follicle transplant survival.
52 citations
,
May 2011 in “APOPTOSIS” Hydroxyl radicals cause hair follicle cell death during chemotherapy by reducing Bcl-2 protein levels.
11 citations
,
March 2010 in “PubMed” IV cyclophosphamide effectively treated severe lupus nephritis in Indian patients.
May 2015 in “Journal of The American Academy of Dermatology” Povidone-iodine nail solution effectively treats nail infections caused by chemotherapy.
1 citations
,
May 2017 in “Journal of Clinical Oncology” Topical calcitriol is safe for preventing hair loss during chemotherapy.
April 2024 in “Lečaŝij vrač” Valproic acid can cause low platelet counts, especially at high doses or in elderly patients.
3 citations
,
February 2010 in “Clinical kidney journal” Combining ciclosporin and simvastatin can cause severe kidney damage.
23 citations
,
December 2013 in “Molecular cancer therapeutics” Breast cancer treatments work better with AR activation, improving results and reducing side effects.
234 citations
,
September 2004 in “Clinical cancer research” BAY 43-9006 helps control kidney cancer growth but doesn't significantly increase overall survival.
60 citations
,
September 2004 in “Pediatric Dermatology” A girl developed vitiligo and psoriasis after hepatitis B treatment, and stopping the treatment didn't help.
July 2024 in “Journal of Investigative Dermatology” INTASYL is a promising, adaptable RNAi technology for treating skin cancers.
VDAC2 promotes cell death in cashmere goat hair follicles through the P53 pathway.
76 citations
,
March 2005 in “Cancer Research” Doxorubicin can block blood vessels from hair follicles, reducing skin tumor growth.
5 citations
,
March 2023 in “PubMed” Advanced therapy medicinal products show promise for vitiligo treatment with fewer side effects, but affordability is a challenge.
January 2010 in “DOAJ (DOAJ: Directory of Open Access Journals)” IV cyclophosphamide effectively treated severe lupus nephritis in Indian patients, but longer follow-up is needed.
Lamivudine might reverse hair graying and needs more research for potential treatments.
April 2017 in “The journal of investigative dermatology/Journal of investigative dermatology” Topical Vorinostat shows promise for treating alopecia areata by promoting hair regrowth.
March 2005 in “Inpharma Weekly” China approved Sinovac's flu vaccine, Japan approved RiUP for female hair loss, and Nippon Kayaku's three cancer drugs.
2 citations
,
January 2016 in “Sarcoma” Inducing survivin in normal tissues can protect against radiation damage.
Vismodegib effectively treats advanced basal cell carcinoma but requires careful management of serious side effects.
22 citations
,
November 2005 in “BMC Cancer” Gemcitabine and paclitaxel are effective and safe as first-line treatment for metastatic breast cancer.